LONDON--(BUSINESS WIRE)--Jul 31, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat aspergillosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180731005909/en/
Technavio has published a new report on the drug development pipeline for aspergillosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Aspergillosis: Market overview
Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune system or those with lung diseases are at high risk of developing health problems due to Aspergillus. There are several kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where fungus causes allergic respiratory symptoms like asthma, wheezing, and coughing, but it does not actually invade and destroy tissues. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune system due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells.
According to a senior market research analyst at Technavio, “As per the Centers for Disease Control and Prevention, milder allergic forms of aspergillosis are more common than the invasive form of the infection. Invasive aspergillosis is uncommon and occurs primarily in immunocompromised people.”
Aspergillosis: Segmentation analysis
This pipeline analysis report segments the aspergillosis market based on therapies employed (monotherapy), RoA (oral, oral/intravenous, inhalation, and intravenous), therapeutic modality (small molecule, bispecific monoclonal antibody, protein, and peptide), targets (ergosterol, CYP51A1, beta-(1,3)-D-glucan synthase, and others), MoA (ergosterol inhibitor, CYP51A1 inhibitor, beta-(1,3)-D-glucan synthase inhibitor, and others), geographical segmentation (the US, Australia, Canada, Russia, Japan, and Europe) and recruitment status (completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, 85% of the molecules that are being investigated for the treatment of aspergillosis are small molecules.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005909/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/31/2018 03:55 PM/DISC: 07/31/2018 03:56 PM